Fluconazole prophylaxis decreases the combined outcome of invasive Candida infections or mortality in preterm infants

Pediatrics

Volumn 122, Issue 5, 2008, Pages 1158-1159

  Kaufman, David ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT;

CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HIGH RISK INFANT; HUMAN; INFANT; INFANT MORTALITY; LETTER; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; CANDIDA; EXTREMELY LOW BIRTH WEIGHT; MICROBIOLOGY; MORTALITY; NEWBORN; NEWBORN INTENSIVE CARE; NOTE; PATHOLOGY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL;

EID: 58149142535     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-1837     Document Type: Letter

References (14)

1. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of flu- conazole-resistant Candida species. Pediatrics. 2008;121(4): 703-710
2. Clerihew L, Austin N, McGuire W. Prophylactic systemic anti- fungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2007;(4): CD003850
3. Kaufman DA. Fluconazole prophylaxis: can we eliminate invasive Candida infections in the neonatal ICU? Curr Opin Pedi- atr. 2008;20(3):332-340
4. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candi-diasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84-92
5. Benjamin DK Jr. First, do no harm. Pediatrics. 2008;121(4): 831-832
6. Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth- weight infants with neonatal infection. JAMA. 2004;292(19): 2357-2365
7. Emanuel EJ, Miller FB. The ethics of placebo-controlled trials: a middle ground. N Engl J Med. 2001;345(12):915-919
8. Centers for Disease Control and Prevention, National Center for Health Statistics. VitalStats. Available at: www.cdc.gov/nchs/ datawh/vitalstats/ VitalStatsbirths.htm. Accessed September 4,2008
9. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics. 2006; 117(5):1680-1687
10. American Academy of Pediatrics. Candidiasis. In: Pickering L, Baker CJ, Long SS, McMillian JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2006:246
11. Clerihew L, Austin N, McGuire W. Systemic antifungal prophylaxis for very-low-birth-weight infants: systematic review. Arch Dis Child Fetal Neonatal Ed. 2008;93(3):F198-F200
12. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal coloniza- tioninthe very low birth weight infant. Pediatrics. 2001;107(2):293-298
13. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345(23):1660-1666
14. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356(24):2483-2495